Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.

Journal of gynecologic oncology - 1 May 2024

Palaia Innocenza, Caruso Giuseppe, Di Donato Violante, Turetta Camilla, Savarese Antonella, Perniola Giorgia, Gallo Roberta, Giannini Andrea, Salutari Vanda, Bogani Giorgio, Tomao Federica, Giannarelli Diana, Gentile Gabriella, Musella Angela, Muzii Ludovico, Pignata Sandro

Abstract excerpt

OBJECTIVE: Early iatrogenic menopause in gynecological cancer survivors and BRCA mutation (BRCAm) carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) is a major health concern. Hormone replacement therapy (HRT) is the most effective remedy, but remains underused in clinical practice. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group promoted a national survey to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Survivors
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Genital Neoplasms, Female

Share to Health Knowledge, Attitudes, Practice

Share to Hormone Replacement Therapy

Share to Practice Patterns, Physicians'

Share to Salpingo-oophorectomy

Source

Open in PubMed Open full text

Identifiers

PMID: 38497108
DOI: 10.3802/jgo.2024.35.e70
PMCID: PMC11107284

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.PMID 38497108Read ↗

BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.Semantic proximity Read ↗

Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.Semantic proximity Read ↗

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.Semantic proximity Read ↗

The perspective of general practitioners on menopause management and hormone replacement therapy in primary care: a cross-sectional studySemantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service.Semantic proximity Read ↗

Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.Semantic proximity Read ↗

Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done.Semantic proximity Read ↗

Uptake of Risk-Reducing Salpingo-Oophorectomy and Gynaecologic Surveillance Among Germline BRCA Pathogenic Variants Carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.